According to the 2018 US Renal Data System (USRDS) report, 88% of the 125,000 incident patients with end-stage kidney disease (ESKD) in the United States select hemodialysis as their kidney replacement modality of choice.1 Among these patients, 80% use a central venous catheter (CVC) at hemodialysis initiation.1 Most patients who initiate hemodialysis with a CVC will subsequently undergo placement of a permanent vascular access: either an arteriovenous fistula (AVF) or an arteriovenous graft (AVG).